Rarely, patients with systemic lupus erythematosus (SLE) develop bullous eruptions, a disease called bullous SLE in a narrow sense that has autoantibodies against type VII collagen. We describe an unusual case in which a patient with SLE developed extensive bullae on her lower extremities. Histologically, the bullous lesions were suggestive of leukocytoclastic vasculitis with deposition of C3 within blood vessel walls. Immunoblot analyses and enzyme-linked immunosorbent assays were negative for anti-type VII collagen antibodies. We initially considered bullous SLE, but eventually made a diagnosis of secondary vasculitis in SLE. The oral prednisolone dose was increased, and the vesiculobullous lesions resolved. The clinical presentations of cutaneous vasculitis in SLE include palpable purpura, petechiae, papulonodular lesions, and livedo reticularis. Bullous lesions seem to be uncommon. Physicians need to be aware that extensive bullae can occur as a result of secondary vasculitis in SLE, even if the patient does not exhibit high disease activity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525288 | PMC |
http://dx.doi.org/10.1159/000519022 | DOI Listing |
Cureus
November 2024
Rheumatology, Cooper University Health Care, Camden, USA.
Drug-induced lupus erythematosus (DILE) is an autoimmune reaction that results in symptoms of polyarthralgia, fever, and cutaneous lesions and other manifestations. Several drugs have been documented to cause this disease, including procainamide, isoniazid, methyldopa, penicillamine, and hydralazine. Systemic lupus erythematosus (SLE) manifestations often occur after the patient has been taking the drug without complications for months to years.
View Article and Find Full Text PDFCurr Rheumatol Rev
December 2024
Specialist Dermatologist, Department of Dermatology, Qassimi Hospital Sharjah.
Background: Systemic Lupus Erythematosus (SLE) (C1) is a disease with multi-organ involvement that can have a variety of cutaneous manifestations in 76% of cases during the disease. Less than 1% of these patients are diagnosed with confirmed bullous systemic lupus erythematosus (C1). Given the wide differential diagnosis of a bullous lesion, it is imperative to reach a conclusive diagnosis as it can have a direct impact on the course of management of the disease.
View Article and Find Full Text PDFClin Cosmet Investig Dermatol
November 2024
The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 31000, People's Republic of China.
Aim: Increasing observational studies are revealing a positive correlation between body mass index (BMI) and the risk of Immune-mediated and Inflammatory Skin Diseases (IMID), however the causal relationship is not yet definite.
Objective: The aim of the study was to conduct a two-sample Mendelian randomization (TSMR) to explore the potential causality between BMI, and IMID and biomarkers.
Methods: The summary statistics for BMI (n = 322,154), at genome-wide significant level, were derived from the Genetic Investigation of Anthropometric Traits consortium (GIANT).
Clin Gastroenterol Hepatol
December 2024
Division of Gastroenterology, University of Utah, Salt Lake City, Utah. Electronic address:
Zhong Nan Da Xue Xue Bao Yi Xue Ban
June 2024
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha 410013.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!